AQUEOUS FORMULATIONS OF AN ANTI-CD22 ANTIBODY AND USES THEREOF
A stable pharmaceutical formulation of a therapeutically active anti-CD22 antibody, Suciraslimab (or SM03), for injection. In particular, the formulations comprising, in addition to a suitable amount of the anti-CD22 antibody.The formulations comprise additionally at least one buffering agent, such...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | SIU, KWAN-YIN LEUNG, SHUI-ON YAU, MING-HON CHEUNG, KA-WA BENNY |
| description | A stable pharmaceutical formulation of a therapeutically active anti-CD22 antibody, Suciraslimab (or SM03), for injection. In particular, the formulations comprising, in addition to a suitable amount of the anti-CD22 antibody.The formulations comprise additionally at least one buffering agent, such as a phosphate buffer and a nonionic surfactant. Methods for preparing such stable formulation and their uses thereof are also provided.
L'invention concerne une formulation pharmaceutique stable d'un anticorps anti-CD22 thérapeutiquement actif, le suciraslimab (ou SM03), pour injection. En particulier, l'invention concerne les formulations comprenant en outre une quantité appropriée de l'anticorps anti-CD22. Les formulations comprennent en outre au moins un agent tampon, tel qu'un tampon phosphate, et un tensioactif non ionique. L'invention concerne également des procédés de préparation d'une telle formulation stable et des utilisations associées. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_CA3235650A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CA3235650A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_CA3235650A13</originalsourceid><addsrcrecordid>eNrjZLBzDAx19Q8NVnDzD_IN9XEM8fT3C1bwd1Nw9AOiEE9dZxcjIzDLyd8lEshwUQgNdg1WCPFwDXL1d-NhYE1LzClO5YXS3AwKbq4hzh66qQX58anFBYnJqXmpJfHOjsZGxqZmpgaOhsZEKAEA5ykpQw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>AQUEOUS FORMULATIONS OF AN ANTI-CD22 ANTIBODY AND USES THEREOF</title><source>esp@cenet</source><creator>SIU, KWAN-YIN ; LEUNG, SHUI-ON ; YAU, MING-HON ; CHEUNG, KA-WA BENNY</creator><creatorcontrib>SIU, KWAN-YIN ; LEUNG, SHUI-ON ; YAU, MING-HON ; CHEUNG, KA-WA BENNY</creatorcontrib><description>A stable pharmaceutical formulation of a therapeutically active anti-CD22 antibody, Suciraslimab (or SM03), for injection. In particular, the formulations comprising, in addition to a suitable amount of the anti-CD22 antibody.The formulations comprise additionally at least one buffering agent, such as a phosphate buffer and a nonionic surfactant. Methods for preparing such stable formulation and their uses thereof are also provided.
L'invention concerne une formulation pharmaceutique stable d'un anticorps anti-CD22 thérapeutiquement actif, le suciraslimab (ou SM03), pour injection. En particulier, l'invention concerne les formulations comprenant en outre une quantité appropriée de l'anticorps anti-CD22. Les formulations comprennent en outre au moins un agent tampon, tel qu'un tampon phosphate, et un tensioactif non ionique. L'invention concerne également des procédés de préparation d'une telle formulation stable et des utilisations associées.</description><language>eng ; fre</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2023</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230427&DB=EPODOC&CC=CA&NR=3235650A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230427&DB=EPODOC&CC=CA&NR=3235650A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>SIU, KWAN-YIN</creatorcontrib><creatorcontrib>LEUNG, SHUI-ON</creatorcontrib><creatorcontrib>YAU, MING-HON</creatorcontrib><creatorcontrib>CHEUNG, KA-WA BENNY</creatorcontrib><title>AQUEOUS FORMULATIONS OF AN ANTI-CD22 ANTIBODY AND USES THEREOF</title><description>A stable pharmaceutical formulation of a therapeutically active anti-CD22 antibody, Suciraslimab (or SM03), for injection. In particular, the formulations comprising, in addition to a suitable amount of the anti-CD22 antibody.The formulations comprise additionally at least one buffering agent, such as a phosphate buffer and a nonionic surfactant. Methods for preparing such stable formulation and their uses thereof are also provided.
L'invention concerne une formulation pharmaceutique stable d'un anticorps anti-CD22 thérapeutiquement actif, le suciraslimab (ou SM03), pour injection. En particulier, l'invention concerne les formulations comprenant en outre une quantité appropriée de l'anticorps anti-CD22. Les formulations comprennent en outre au moins un agent tampon, tel qu'un tampon phosphate, et un tensioactif non ionique. L'invention concerne également des procédés de préparation d'une telle formulation stable et des utilisations associées.</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2023</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZLBzDAx19Q8NVnDzD_IN9XEM8fT3C1bwd1Nw9AOiEE9dZxcjIzDLyd8lEshwUQgNdg1WCPFwDXL1d-NhYE1LzClO5YXS3AwKbq4hzh66qQX58anFBYnJqXmpJfHOjsZGxqZmpgaOhsZEKAEA5ykpQw</recordid><startdate>20230427</startdate><enddate>20230427</enddate><creator>SIU, KWAN-YIN</creator><creator>LEUNG, SHUI-ON</creator><creator>YAU, MING-HON</creator><creator>CHEUNG, KA-WA BENNY</creator><scope>EVB</scope></search><sort><creationdate>20230427</creationdate><title>AQUEOUS FORMULATIONS OF AN ANTI-CD22 ANTIBODY AND USES THEREOF</title><author>SIU, KWAN-YIN ; LEUNG, SHUI-ON ; YAU, MING-HON ; CHEUNG, KA-WA BENNY</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_CA3235650A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2023</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>SIU, KWAN-YIN</creatorcontrib><creatorcontrib>LEUNG, SHUI-ON</creatorcontrib><creatorcontrib>YAU, MING-HON</creatorcontrib><creatorcontrib>CHEUNG, KA-WA BENNY</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>SIU, KWAN-YIN</au><au>LEUNG, SHUI-ON</au><au>YAU, MING-HON</au><au>CHEUNG, KA-WA BENNY</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>AQUEOUS FORMULATIONS OF AN ANTI-CD22 ANTIBODY AND USES THEREOF</title><date>2023-04-27</date><risdate>2023</risdate><abstract>A stable pharmaceutical formulation of a therapeutically active anti-CD22 antibody, Suciraslimab (or SM03), for injection. In particular, the formulations comprising, in addition to a suitable amount of the anti-CD22 antibody.The formulations comprise additionally at least one buffering agent, such as a phosphate buffer and a nonionic surfactant. Methods for preparing such stable formulation and their uses thereof are also provided.
L'invention concerne une formulation pharmaceutique stable d'un anticorps anti-CD22 thérapeutiquement actif, le suciraslimab (ou SM03), pour injection. En particulier, l'invention concerne les formulations comprenant en outre une quantité appropriée de l'anticorps anti-CD22. Les formulations comprennent en outre au moins un agent tampon, tel qu'un tampon phosphate, et un tensioactif non ionique. L'invention concerne également des procédés de préparation d'une telle formulation stable et des utilisations associées.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre |
| recordid | cdi_epo_espacenet_CA3235650A1 |
| source | esp@cenet |
| subjects | CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | AQUEOUS FORMULATIONS OF AN ANTI-CD22 ANTIBODY AND USES THEREOF |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T06%3A51%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=SIU,%20KWAN-YIN&rft.date=2023-04-27&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ECA3235650A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |